Netilmicin | CMAC

Netilmicin

Clinical Microbiology and Antimicrobial Chemotherapy. 2007; 9(3):253-267

​ Reshedko G.K.
aminoglycosides netilmicin microbial resistance pharmacodynamis review
Section
Antimicrobials
Type
Journal article
Publication
Clinical Microbiology and Antimicrobial Chemotherapy. 2007; 9(3):253-267

Abstract

In spite of development of number of new antimicrobials of other classes, aminoglycosides are still widely used in clinical practice. Their rapid bactericidal activity against the majority of common human pathogens as well as synergism with some other antimicrobials such as b-lactams and glycopeptides allow usage of these agents for treatment of nosocomial and some communityacquired infections. One of the most interesting representatives of aminoglycosides – netilmicin, is described in detail in this literature review.

  • 1. Cho J., Hamasaki K., Rando R.R. The binding site of a specific aminoglycoside binding RNA molecule. Biochemistry 1998; 37:4985-92.
  • 2. Wallis M.G., Schroeder R. The binding of antibiotics to RNA. Prog Biophys Mol Biol 1997; 67:141-54.
  • 3. Bryan L.E. Mechanisms of action of aminoglycoside antibiotics. In: Contemporary issues in infectious diseases. Root R.K., Sande M.A., eds. New York: Churchill Livingstone 1984; 1:17-36.
  • 4. Taber H.W., Muller J.P., Arrow A.S. Bacterial uptake of aminoglycoside antibiotics. Microbiol Rev 1987; 51:439-57.
  • 5. Hermann T., Westhoff E. Aminoglycoside binding to the hammerhead ribozyme: a general model for the interaction of cationic antibiotics with RNA. J Mol Biol 1998; 276:903-12.
  • 6. Jackson G.E., Lolans V.T., Daikos G.L. The inductive role of ionic binding in the bactericidal and postexposure effects of aminoglycoside antibiotics with implications for dosing. J Infect Dis 1990; 162:408-13.
  • 7. Reller L.B., Schoenknecht F.D., Kenny M.A., et al. Antibiotic susceptibility testing of Pseudomonas aeruginosa: selection of a control strain and criteria for magnesium and calcium content in media. Antimicrob Agents Chemother 1987; 31:1514-8.
  • 8. Damper P.D., Epstein W. Role of the membrane potencial in bacterial resistance to aminoglycoside antibiotics. Antimicrob Agents Chemother 1981; 20:803-8.
  • 9. Harrell L.R., Evans L.B. Anaerobic resistance of clinical isolates of Staphylococcus aureus to aminoglycosides. Antimicrob Agents Chemother 1978; 14:927-9.
  • 10. Bryan L.E., Kowand S.K., Van Den Elzen H.M. Mechanism of aminoglycoside antibiotic resistance in anaerobic bacteria. Clostridium perfringens and Bacteroides fragilis. Antimicrob Agents Chemother 1979; 15:7-13.
  • 11. Kantor R.J., Norden C.W. In vitro activity of netilmicin, gentamicin and amikacin. Antimicrob Agents Chemother 1977; 11:126-31.
  • 12. Meyers B.R., Hirschman S.Z. Antimicrobial activity in vitro of netilmicin and comparison with sisomicin, gentamicin, and tobramicin. Antimicrob Agents Chemother 1977; 11:118-21.
  • 13. Rahal J.J., Simberkoff M.S., Kagan K., et. al. Bactericidal efficacy of Sch 20569 and amikacin against gentamicinsensitive and –resistant organisms. Antimicrob Agents Chemother 1976; 9:595-99.
  • 14. Phillips I., Shannon K.P.. Aminoglycosides and aminocyclitols. In: Antibiotic and Chemotherapy. O'Grady F.O., Lambert H.P., Finch R.G., Greenwood D., eds.; 2003.
  • 15. Naber KG, Grimm H, Rosenthal EJ, et. al. Resistance to aminoglycosides: the situation in the Federal Republic of Germany. J Int Med Res 1990; 18 Suppl 4:6D-26D.
  • 16. Gospodarek E. Susceptibility to antibiotics and biochemical activity of strains Acinetobacter spp., isolated from various sources. Med Dosw Microbiol 1993; 45:331-7.
  • 17. Nemec A, Maixnerová M. Aminoglycoside resistance of Acinetobacter baumannii hospital strains in the Czech Republic. Klin Mikrobiol Infekc Lek 2004; 10:223-8.
  • 18. Hanberger H., Erlandsson M., Burman L.G., et. al. High antibiotic susceptibility among bacterial pathogens in Swedish ICUs. Report from a nation-wide surveillance program using TA90 as a novel index of susceptibility. Scand J Infect Dis 2004; 36:24-30.
  • 19. Mittermayer H., Rotter M., Breitfellner G., et. al Resistance of gram-negative bacilli and staphylococci from blood cultures to aminoglycoside antibiotics. Comparison of 3 in vitro investigations from Austria 1982-1988. Zentralbl Bakteriol 1990; 272:448-57.
  • 20. Quentin C., Grobost F., Fischer I., et. al. Antibiotic resistance of Staphylococcus aureus in urban experience: 6 month study in Aquitaine. Pathol Biol 2001; 49:33- 40.
  • 21. Stratchounski L.S., Shevelev A.N., Korovina N.A., et al. Resistance of E.coli isolated from children with community-acquired urinary tract infections (CA_UTI) in Russia^ results of multicenter study ARMID. Proceeding of 42nd Intersciience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 2002, San Diego, P.253, Abstr. G-1469.
  • 22. Сидоренко С.В., Резван С.П., Еремина Л.В. и др. Этиология тяжелых госпитальных инфекций в отделениях реанимации и антибиотикорезистентность среди их возбудителей. Антибиотики и химиотер 2005; 50:33-41.
  • 23. Розанова С.М., Руднов В.А., Перевалова Е.Ю. и др. Сравнительный анализ этиологии и антибиотикорезистентности основных возбудителей нозокомиальных инфекций в ОРИТ различного профиля города Екатеринбурга. Клин микробиол антимикроб химиотер 2005; 7:410-8.
  • 24. Isaksson B., Maller R., Nilsson L.E., et. al. Postantibiotic effect of aminoglycosides on staphylococci. J Antimicrob Chemother 1993; 32:215-22.
  • 25. Majtánová L, Majtán V. Postantibiotic effects of gentamicin and netilmicin on Serratia marcescens: effects on hydrophobicity and motility. Folia Microbiol 2000; 45:45-9.
  • 26. Bonfiglio G., Scuderi A.C., Russo G. Netilmicin: in vitro activity, time-kill evaluation and postantibiotic effect on microorganisms isolated from ocular infectious. Chemotherapy 2001; 47:117-22.
  • 27. Anding K., Krumme B., Pelz K., et.al. Pharmacokinetics and bactericidal activity of a single daily dose of netilmicin in the treatment of CAPD-associated peritonitis. Int J Clin Pharmacol Ther 1996; 34:465-9.
  • 28. Majtán V., Hostacká A. Influence of the postantibiotic effect and postantibiotic sub-MICs effect of netilmicin, tobramycin, ciprofloxacin and pefloxacin on alginate production by Pseudomonas aeruginosa. Folia Microbiol 1996; 41:228-32.
  • 29. Xiong Y.Q., Caillon J., Drugeon H., et. al. Influence of pH on adaptive resistance of Pseudomonas aeruginosa to aminoglycosides and their postantibiotic effects. Antimicrob Agents Chemother 1996; 40:35-9.
  • 30. Rochon-Edouard S., Pestel-Caron M., Lemeland J.F., et. al. In vitro synergistic effects of double and triple combinations of beta-lactams, vancomicin, and netilmicin against meticillin-resistant Staphylococcus aureus strains. Antimicrob Agents Chemother 2000; 44: 3055-60.
  • 31. Fantin B., Carbon C. Importance of the aminoglycoside dosing regimen in the penicillin-netilmicin combination for treatment of Enterococcus faecalis-induced experimental endocarditis. Antimicrob Agents Chemother 1990; 34:2387-91.
  • 32. Rahal J.J., Simberkoff M.S. Comparative bactericidal activity of penicillin-netilmicin and penicillin-gentamicin against enterococci. J Antimicrob Chemother 1986; 17:585-91.
  • 33. Chavanet P., Collin F., Muggeo E., et. al. The in vivo activity of co-amoxiclav with netilmicin against experimental methicillin and gentamicin resistant Staphylococcus epidermidis infection in rabbits. J Antimicrob Chemother 1993; 31:129-38.
  • 34. Francioli PB, Glauser MP. Synergistic activity of ceftriaxone combined with netilmicin administered once daily for treatment of experimental streptococcal endocarditis. Antimicrob Agents Chemother 1993; 37:207-12.
  • 35. Duez J.M., Siebor E., Pechinot A., et. al. A. In vitro antibacterial activity of piperacillin-tazobactam in combination with netilmicin or amikacin against Enterobacteriaceae resistant to amoxicillin. Pathol Biol 1995; 43:208-14.
  • 36. Arpi M. Time-kill studies and synergy testing of broadspectrum antibiotics against blood culture isolates. Chemotherapy 1988; 34:393-400.
  • 37. Baumgärtner M., Müller H.P., Wundt W. Antibiotic activity and synergism of ceftazidime and netilmicin against gram-negative pathogenic bacteria. Arzneimittelforschung 1983; 33:1615-9.
  • 38. Yamashiro Y., Ogake N., Takahata M., et. al. In vitro interaction of piperacillin and imipenem/cilastatin combined with aminoglycosides against Pseudomonas aeruginosa. Jpn J Antibiot 2000; 53:194-200.
  • 39. Shaw K.J., Rather P.N., Hare R.S. et. al. Molecular genetics of aminoglycoside resistance genes and familial relationships of the aminoglycoside-modifying enzymes. Microbiol Rev 1993; 57:138-63.
  • 40. Яковлев В.П. Нетилмицин. Антибиотики и химиотер 1993; 38:69-86.
  • 41. Ettlinger J.J., Bedford K.A., Lovering A.M., et. al. Pharmacokinetics of once-a-day netilmicin (6 mg/kg) in neonates.J Antimicrob Chemother 1996; 38:499-505.
  • 42. Tréluyer J.M., Merlé Y., Semlali A., et. al. Population pharmacokinetic analysis of netilmicin in neonates and infants with use of a nonparametric method. Clin Pharmacol Ther 2000; 67:600-9.
  • 43. Wagner B.P., Pfenninger J. Once daily dosing of netilmicin in neonatal and pediatric intensive care. Intensive Care Med 1994; 20:365-7.
  • 44. Welling P.C., Baumueller A., Lau C.C. et al. Antimicrob Agents Chemother 1977; 12:328:34.
  • 45. Lanao J.M., Lopez A., Dominguez-Gil A., et. al. Distribution kinetics of netilmicin in human blister fluid: effect of renal impairment. Biopharm Drug Dispos 1991; 12:149-62.
  • 46. Martin C., Portet C., Bantz P., et. al. Pharmacokinetics and tissue penetration of single-dose netilmicin used for antibiotic prophylaxis during colo-rectal surgery. Pathol Biol 1990; 39:507-10.
  • 47. Hielte L., Malmborg A.S., Strandvick B. Serum and sputum concentrations of netilmicin in combination with acylureidopenicillin and cephalosporins in clinical treatment of pulmonary exacerbations in cystic fibrosis. J Antimicrob Chemother 1989; 23:885-90.
  • 48. Bruckner O., Trautmann M., Kolodziejczyk D., et. al. Netilmicin in human CSF after parenteral administration in patients with slightly and severely impaired blood CSF barrier. J Antimicrob Chemother 1983; 11:565-71.
  • 49. Kahlmeter G., Dahlager JI. Aminoglycoside toxicity – a review of clinical studies published between 1975 and 1982. JAC 1984; 13 Suppl. A: 9.
  • 50. Gorse G.J., Bernstein J.M., Cronin R.E., et. al. A comparison of netilmicin and tobramycin therapy in patients with renal impairment. Scand J Infect Dis 1992; 24:503- 14.
  • 51. Bhattacharya B.K., Gorringe H., Farr M.J. Netilmicin and nephrotoxicity. Lancet 1983 23; 2:216-7.
  • 52. Andronikou S., Giapros V.I., Cholevas V.I., et. al. Once daily dosing of netilmicin in neonatal and pediatric intensive care. Pediatr Nephrol 1996; 10:766-8.
  • 53. Giapros V.I., Andronikou S., Cholevas V.I., et. al. Renal function in premature infants during aminoglycoside therapy. Pediatr Nephrol 1995; 9:163-6.
  • 54. Santos M., Arevalo M., Colino C.I., et. al. Study on pharmacokinetics and nephrotoxicity of netilmicin in rabbits using a new dosage regimen. Methods Find Exp Clin Pharmacol 1997; 19:53-9.
  • 55. Fantin B., Carbon C. Importance of the aminoglycoside dosing regimen in the penicillin-netilmicin combination for treatment of Enterococcus faecalis-induced experimental endocarditis. Antimicrob Agents Chemother 1990; 34:2387-91.
  • 56. Blaser J., Simmen H.P., Thurnheer U., et. al. Nephrotoxicity, high frequency ototoxicity, efficacy and serum kinetics of once versus thrice daily dosing of netilmicin in patients with serious infections. J Antimicrob Chemother 1995; 36:803-14.
  • 57. Van der Auwera P., Meunier F., Ibrahim S., et. al. Pharmacodynamic parameters and toxicity of netilmicin (6 milligrams/kilogram/day) given once daily or in three divided doses to cancer patients with urinary tract infection. Antimicrob Agents Chemother 1991; 35:640-7.
  • 58. Tulkens P.M. Pharmacokinetic and toxicological evaluation of a once-daily regimen versus conventional schedules of netilmicin and amikacin. J Antimicrob Chemother 1991; 27, Suppl C:49-61.
  • 59. Vigano A., Principi N., Brivio L., et. al. Comparison of 5 milligrams of netilmicin per kilogram of body weight once daily versus 2 milligrams per kilogram trice daily for treatment gram-negative pyelonephritis in children. Antimicrob Agents Chemother 1992; 36:1499-503.
  • 60. Ferriols-Lisart R., Alos-Alminana M. Effectiveness and safety of once-daily aminoglycosides: a meta-analysis. Am J Health Syst Pharm 1996; 53:1141-50.
  • 61. Blaser J. Dosing aminoglycosides once a day. Schweiz Med Wochenschr Suppl 1996; 76:39S-48S.
  • 62. Laczika K., Staudinger T., Hollenstein U., et. al. Renal tolerability of four different once-daily dose regimen of netilmicin in critical care patients. Wien Klin Wochenschr 1997; 109:840-4.
  • 63. Gosden P.E., Bedford K.A., Dixon J.J., et. al. Pharma­cokinetics of once-a-day netilmicin (4.5 mg/kg) in neonates. J Chemother 2001; 13:270-6.
  • 64. Nayir A., Sirin A., Emre S., et. al. Pharmacokinetics of amikacin, netilmicin and tobramycin in children with chronic renal failure. Turk J Pediatr 1995; 37:111-6.
  • 65. Blaser J., Konig C., Simmen H.P., et. al. Monitoring serum concentrations for once-daily netilmicin dosing regimens. J Antimicrob Chemother 1994; 33:341-8.
  • 66. Henning C., Medén-Britth G., Frölander F., et. al. Comparative study of netilmicin/tinidazole versus netilmicin/ clindamycin in the treatment of severe abdominal infections. Scand J Infect Dis 1984; 16:297-303.
  • 67. Bailey R.R., Lynn K.L., Robson R.A., et. al. Comparison of ciprofloxacin with netilmicin for the treatment of acute pyelonephritis. N Z Med J 1992; 105:102-3.
  • 68. Caramalli S., Amprimo M.C., Cavalli G., et. al. Effect and pharmacokinetics of netilmicin given as bolus intramuscular administration: an open comparative trial versus amikacin and fosfomycin in elderly patients affected by urinary tract infections. Int J Clin Pharmacol Res 1991; 11:55-65.
  • 69. Fridmond-Moller N., Maigaard S., Madsen P.O. Netilmicin treatment of complicated urinary tract infection in patients with renal function impairment. Antimicrob Agents Chemother 1979; 16:406-10.
  • 70. Francioli P., Ruch W., Stamboulian D. Treatment of streptococcal endocarditis with a single daily dose of ceftriaxone and netilmicin for 14 days: a prospective multicenter study. Clin Infect Dis 1995; 21:1406-10.
  • 71. Sobliati M. The impact of novel dosing regimens on the safety and afficacy of aminoglycosides. Symp. in Sorento, Italy 1987:149-152.
  • 72. Laszlo D., Bacci S., Bosi A., et. al. Randomized trial comparing netilmicin plus imipenem-cilastatin versus netilmicin plus ceftazidime as empiric therapy for febrile neutropenic bone marrow transplant recipients. J Chemother 1997; 9:95-101.
  • 73. Studena M., Hlavacova E., Hel’pianska L., et al. Teicoplanin plus pefloxacine versus teicoplanin plus netilmicin in empiric therapy of febrile patients with cancer and neutropenia. A randomized study of two once daily regimens in patients with previously inserted catheters. Chemotherapy 1994; 40:431-4.
  • 74. Martin C., Portet C., Bantz P., et. al. Pharmacokinetics and tissue penetration of single-dose netilmicin used for antibiotic prophylaxis during colo-rectal surgery. Pathol Biol 1991; 39:507-10.
  • 75. Luzuriaga Graf J., Sanchez Chavez O., Arauz Arauz E. Antimicrobial prophylaxis in urologic surgery Arch Esp Urol 1990; 43:715-8.
  • 76. Scarpa R.M., Cossu F.M., Ambus G., et. al. Antibiotic prophylaxis with netilmicin in patients undergoing cystoscopic study. Minerva Urol Nefrol 1990; 42:167-71.
  • 77. McCormick P.A., Greenslade L., Kibbler C.C., et. al. A prospective randomized trial of ceftazidime versus netilmicin plus mezlocillin in the empirical therapy of presumed sepsis in cirrhotic patients. Hepatology 1997; 25:833-6.
  • 78. Prins J.M., Buller H.R., Kuijper E.J., et. al. Once-daily gentamicin versus once-daily netilmicin in patients with serious infections--a randomized clinical trial. J Antimicrob Chemother 1994; 33:823-35.
  • 79. Tange R.A., Dreschler W.A., Prins J.M., et. al. Ototoxicity and nephrotoxicity of gentamicin vs netilmicin in patients with serious infections. A randomized clinical trial. Clin Otolaryngol 1995; 20:118-23.
Views
0 Abstract
0 PDF
0 Crossref citations
Shared